ChemoMetec A/S/€CHEMM

1D1W1MYTD1Y5YMAX

About ChemoMetec A/S

ChemoMetec A/S is engaged in the development, manufacturing, and marketing of analytical instruments used for counting and analyzing cells in a variety of applications across biotechnology, pharmaceuticals, and academic research sectors. The company’s main product lines include automated cell counters and analyzers, such as the NucleoCounter series. Founded in 1997, ChemoMetec is headquartered in Allerod, Denmark. The company is noted for its focus on innovation in cell counting technology, providing precise and user-friendly solutions that facilitate laboratory workflows and enhance data accuracy. Its strategic position in the analytical instruments industry is strengthened by its commitment to quality and reliability in measurement instrumentation.
Ticker
€CHEMM
Sector
Health
Primary listing
XGAT
Employees
174
Headquarters
Allerød, Denmark
Website
chemometec.com

ChemoMetec A/S Metrics

BasicAdvanced
€1.2B
44.51
€1.55
1.39
€0.94
1.36%

Bulls say / Bears say

ChemoMetec’s product transition is gaining traction: XcytoMatic sales rose from DKK 27.7 million to DKK 61.8 million, while total instrument sales increased 13%. Management expects 2026/27 revenue of DKK 545–575 million and EBITDA of DKK 300–315 million. (ChemoMetec, ChemoMetec)
The shift towards automated bioprocessing creates a larger growth opportunity than ChemoMetec’s legacy cell-counting market. Its XcytoMatic platform, software development and partnerships are designed to integrate into customers’ automated workflows, while a reported Roche collaboration could materially expand future instrument and recurring aftermarket sales. (ChemoMetec, MedWatch)
Profitability remains a major strength. 2025/26 EBITDA rose 9% to DKK 281.3 million, the margin reached 55% from 52%, and net profit increased to DKK 201.8 million, giving the company scope to fund product development and return capital through buy-backs. (ChemoMetec)
Underlying growth has slowed sharply: reported revenue rose only 3% to DKK 511.1 million in 2025/26, while consumables fell 4%. Customers directing spending towards future automation and treating fewer patients have reduced activity in older approved therapies and weakened the recurring-revenue base. (ChemoMetec, ChemoMetec)
Execution risk is high because automation projects are large, cross-border programmes involving lengthy validation and approval processes. ChemoMetec said these implementations were taking longer than expected, contributing to prolonged customer decisions and a March 2026 guidance reduction. (ChemoMetec)
The business remains exposed to North American demand and currency movements: the USA and Canada represented 54% of revenue, yet regional revenue fell 6% in reported terms in 2025/26. Further uncertainty comes from the partnership pipeline, as management’s 2026/27 guidance excludes Roche, Tecan and Hamilton revenue until purchase orders are received. (ChemoMetec, Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.